Such a well run company. We expected the expenses to increase with the ramp up of NNZ-2591 but it's just unreal our net FX gain for the quarter has covered our entire R&D spend over that same period. Another thing to note, it is good to see that the staff & general corporate expenses remaining reasonable (as a %) compared to our R&D spend which is a good sign.
- Forums
- ASX - By Stock
- NEU
- Ann: Q3 2023 quarterly activity and cash flow report
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.00%
!
$13.24

Ann: Q3 2023 quarterly activity and cash flow report, page-10
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.24 |
Change
0.385(3.00%) |
Mkt cap ! $1.652B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $4.381M | 333.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 118 | $13.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.24 | 524 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 187 | 13.230 |
5 | 399 | 13.220 |
3 | 554 | 13.210 |
10 | 2227 | 13.200 |
6 | 1852 | 13.190 |
Price($) | Vol. | No. |
---|---|---|
13.240 | 665 | 13 |
13.250 | 2297 | 22 |
13.260 | 2298 | 14 |
13.270 | 1620 | 9 |
13.280 | 2926 | 7 |
Last trade - 12.30pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online